AI Drug Discovery for Pharma and Biotech

Drug discovery

19

drugs

With orphan designations

Overview

Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder caused by TSC1 or TSC2 gene mutations, leading to mTOR pathway dysregulation and multi-organ hamartomas. Clinical features include epilepsy, TSC-associated neuropsychiatric disorders (TAND), renal angiomyolipomas, cardiac rhabdomyomas, and dermatologic manifestations. Diagnosis involves genetic testing and clinical criteria, with surveillance for systemic complications [1][2][18].

Population

  • Incidence: 1 in 6,000–10,000 live births, affecting ~50,000 in the U.S. and ~2 million globally [1][7][17].

  • Prevalence varies by region, e.g., 4.69 per 100,000 in France and 7.9 per 100,000 in Germany [4][9].

Burden

  • Economic burden: Annual healthcare costs exceed €11,000 per patient with epilepsy, driven by medications, hospitalizations, and specialist care [4][9][14].

  • Morbidity/mortality: Neurologic sequelae (90% epilepsy, 40–50% intellectual disability) and renal complications are leading causes of morbidity; mortality linked to seizures, renal failure, or SEGAs [1][4][14].

  • Quality of life: TAND affects ~85% of patients, contributing to educational/career disruptions and caregiver strain [1][14].

Therapies

  • mTOR inhibitors (sirolimus, everolimus): Reduce tumor growth, manage refractory epilepsy, and improve pulmonary/renal outcomes [8][10][13].

  • Epilepsy management: Antiseizure medications (e.g., vigabatrin for infantile spasms), surgical resection of epileptogenic foci, and early seizure control to mitigate cognitive deficits [3][8][13].

  • Multidisciplinary care: Dermatologic interventions (e.g., mTOR inhibitor creams), renal surveillance, and neurodevelopmental support [6][13][16].

Categories: rare circulatory system diseases, rare developmental anomalies during embryogenesis, rare genetic diseases, rare neoplastic diseases, rare neurological diseases, rare renal diseases, rare skin diseases, rare transplant-related disorders

Research Papers

2,525 drug discovery papers about Tuberous sclerosis complex, with 2 first-in-class and 29 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

2,525 drug discovery papers about Tuberous sclerosis complex, with 2 first-in-class and 29 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

small molecules
2026-09-30 | Hepatic PEComas ‒ A national multicenter study. Clinical, pathological, and surgical outcomes.

PEComas are neoplasms originating from perivascular epithelioid cells. Their incidence is higher in patients with tuberous sclerosis; however, hepatic PEComas are exceptionally rare compared to those in other locations. Diagnostic confirmation relies on histopathological findings and immunohistochemical phenotypes. To evaluate the clinical-radiological presentation, histopathological characteristics, and surgical outcomes of a multicenter cohort of hepatic PEComas. A retrospective, multicenter, nationwide observational study of patients with histologically confirmed hepatic PEComa who underwent surgery at Spanish centers between 2010 and 2024. Twenty-two patients were included; 21 (95.5%) were women, with a mean age of 54.7 years. Mean tumor size was 4.3 cm. Preoperative radiological diagnosis was challenging, with PEComa identified in only one case (4.5%). Preoperative biopsy was performed in 8 patients, yielding a diagnosis of PEComa in 6 cases (75%). Surgical procedures consisted of minor hepatectomy in 14 patients (63.6%) and major hepatectomy in 8 patients (36.4%). The 90-day mortality rate was 0%. Mean hospital stay was 4.5 days. Immunohistochemical analysis was positive for: HMB45 (19 patients, 90.5%), Melan-A (17, 81%), and actin (13, 61.9%). After a median follow-up of 49 months, no recurrences were detected. Preoperative diagnosis of PEComa poses a radiological challenge, frequently requiring biopsy for confirmation. Surgical treatment was not associated with mortality, showed a relevant complication rate of 18.2%, and no recurrences were observed.

Open article ↗



2026-09-21 | Case Report: Presymptomatic risdiplam in preterm monozygotic twins with co-occurring spinal muscular atrophy and tuberous sclerosis complex.

Spinal muscular atrophy (SMA) and tuberous sclerosis complex (TSC) are both rare genetic disorders, and their co-occurrence is expected to be exceptionally uncommon. Although risdiplam has demonstrated efficacy in SMA, evidence regarding its use in preterm infants with complex genetic comorbidities remains limited. We report preterm monozygotic twins born at 32+5 weeks of gestation with genetically confirmed SMA caused by homozygous deletion of SMN1 exons 7-8, with two copies of SMN2. During baseline evaluation prior to presymptomatic treatment, brain magnetic resonance imaging revealed incidental abnormalities, including cortical dysplasia and subependymal nodules, which prompted further genetic testing and led to the diagnosis of TSC with a TSC1 c.1041G>A variant. Presymptomatic risdiplam was initiated at a corrected gestational age of 38+5 weeks. Both twins showed marked improvement in motor function. By 12 months of age, they had achieved independent rolling, unsupported sitting, crawling, and pulling to stand, accompanied by substantial improvements in CHOP INTEND and HINE-2 scores. Risdiplam was well tolerated, and no commonly reported adverse events were observed during follow-up. This report describes the first documented co-occurrence of SMA and TSC in preterm monozygotic twins and suggests that presymptomatic risdiplam may be effective and well tolerated in this complex clinical setting over 1 year of follow-up. These findings also highlight the importance of comprehensive genetic evaluation in infants with SMA who present with atypical neuroimaging or neurological features. Longer-term follow-up is needed to clarify safety, efficacy, and optimal integrated management strategies in patients with complex genetic comorbidities.

Open article ↗



2026-09-21 | Effectiveness and safety of cannabidiol in adult patients with epilepsy: A multicenter, retrospective study.

Cannabidiol (CBD) has demonstrated promising effectiveness and tolerability as adjunctive treatment in patients with severe childhood epilepsies. This study investigated the effectiveness and tolerability of CBD in adults with a history of Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC). This was a multicenter, retrospective, observational study in adults with diagnosis of DS, LGS or TSC who received at least 12 months of CBD treatment. Medical records were reviewed and baseline characteristics, treatment retention, seizure frequency, cognitive behavioral improvements, concomitant ASM usage, and adverse events were assessed. Thirty-seven patients (median age 25 years; 67.5% male) with diagnosis of DS, LGS or TSC received CBD for at least 12 months. The CBD median maintenance dose was 10.45 mg/kg/day (IQR 7.455 - 13.975) (median maximum dose 11 mg/kg/day); median follow-up time was 28 months (IQR 22.75-58.25). Seizure frequency was reduced by ≥50% in 48.6% of patients at 6 months and 45.9% at 12 months. No statistically significant differences in median maintenance dose were observed across seizure reduction categories. During CBD treatment, caregivers reported subjective improvements in cognition in 29.7% of patients. Treatment with CBD was significantly associated with a reduction in the median number of concomitant ASMs at the end of follow-up (4 [3, 4]) vs. 3 [3, 4] (p = 0.022). AEs occurred in 64.9% of patients and were mostly mild; 16.2% had AEs leading to treatment discontinuation. We present a series of adult patients treated with CBD according to label. The results are similar to those described in children. CBD treatment was associated with clinically meaningful seizure reduction and acceptable tolerability in this real-world cohort of adults with drug-resistant developmental and epileptic encephalopathies. These findings support the potential role of CBD in complex adult DEE populations while highlighting the need for prospective controlled studies to better define its independent treatment effect. This study looked at the long-term use of cannabidiol (CBD) in 37 adults with Dravet syndrome, Lennox-Gastaut syndrome, or tuberous sclerosis complex. After 12 months, almost half of the patients had at least a 50% reduction in seizures. Some caregivers also reported improvements in cognition and behavior. Patients were able to reduce the number of other antiseizure medicines they were taking. Side effects were common but mostly mild, although a small number of patients stopped treatment because of them. Overall, CBD appeared effective and reasonably well tolerated, but further controlled studies are needed.

Open article ↗



2026-09-19 | Tryptophan-enriched diet improves social behavior in a mouse model of tuberous sclerosis complex.

Background: Tryptophan is an essential dietary amino acid and the sole precursor of serotonin (5-HT), a neurotransmitter that plays a key role in cognition, mood regulation, and sensory processing. Because central serotonin synthesis depends on dietary tryptophan availability, nutritional modulation of tryptophan intake has emerged as a potential strategy to influence brain function and behavior. Disruptions in tryptophan metabolism and serotonergic signaling have been implicated in autism spectrum disorder (ASD), particularly in Tuberous Sclerosis Complex (TSC), a neurogenetic condition frequently associated with ASD. In this study, we investigated whether dietary tryptophan supplementation could modulate brain tryptophan metabolism and improve ASD-related behaviors in the Tsc2+/- mouse model. Methods: For that, behavioral tests were performed together with in vivo magnetic resonance spetrosocopy (1H-MRS) and ex vivo high-performance liquid chromatography (HPLC). Results: Behavioral analysis revealed sex-specific improvements following supplementation, including enhanced sociability in females, restoration of social novelty preference in males, and reduced anxiety-like behavior accompanied by increased exploratory activity across groups. These behavioral changes were associated with increased cortical tryptophan levels, as determined by high-performance liquid chromatography. However, no significant alterations in cortical excitation/inhibition balance were detected using in vivo proton magnetic resonance spectroscopy. Conclusions: Together, these findings demonstrate that dietary tryptophan supplementation enhances cortical tryptophan availability and ameliorates ASD-like behavioral phenotypes in Tsc2+/- mice. Our results highlight the potential of nutritional modulation of tryptophan intake as a non-invasive strategy to influence serotonergic pathways and behavioral outcomes, supporting the development of precision nutrition approaches for neurodevelopmental disorders.

Open article ↗



2026-09-17 | Use of Purified Cannabidiol in Treatment-Resistant Pediatric Epilepsy: Beyond Lennox-Gastaut Syndrome, Dravet Syndrome, and Tuberous Sclerosis Complex.

The pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex) is approved by the the US Food and Drug Administration for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis in patients one year of age and older. Among the large volume of drug-resistant cases treated at pediatric Level 4 Epilepsy Centers, many patients fall outside of these categories but are still prescribed CBD for off label use. This study sought to characterize the real-world experience with CBD of a large single pediatric comprehensive epilepsy center and to compare response to CBD within and outside of its FDA-approved indications. A retrospective chart review was performed of patients with a prescription for CBD at our institution between January 2020 and January 2022, excluding patients who were previously included in our center's 2019 analysis. Patients were not included in the analysis if initially prescribed CBD elsewhere, follow-up was outside our institution, medication was not started, patient expired during the study period, or diagnostic data was not available. Between-group differences were assessed via Wilcoxon rank-sum and Fisher exact tests, as appropriate. Of 223 patients with a CBD prescription during the study period, 144 patients had sufficient data available for review. Of these patients, 81 (56%) carried diagnoses of Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis, and 63 (44%) carried other diagnoses outside of FDA-labeled indications. Median (interquartile range) age at initiation was 10.0 years (5.0, 13.0), and median (interquartile range) number of concurrent anti-seizure medications was 3.0 (2.0, 3.0). There was no significant difference in the proportion of patients treated concurrently with vagus nerve stimulation or ketogenic diet between the two groups. The FDA-labeled (63%) group had a significantly higher proportion of patients with tonic seizures compared to the non-FDA labeled (29%) group (P < 0.001), otherwise there were no significant differences in baseline seizure types. Overall, 53 patients (65%) in the FDA-labeled group and 40 (63%) of the non-FDA labeled group had a documented responder rate at least 50% on CBD (P = 0.9). The most common side effects reported were nausea/diarrhea/gastrointestinal upset (19%), agitation (7.6%), insomnia (4.9%), weight loss (6.3%), and secretions/drooling (2.8%, seen only in patients on concurrent clobazam). Among our cohort of treatment-resistant pediatric epilepsy, purified CBD was efficacious in a broad range of pediatric epilepsies and was well tolerated as an adjunctive anti-seizure medication. This medication may be considered in pharmacoresistant pediatric epilepsies in conditions beyond its FDA-labeled indications.

Open article ↗



proteins
2026-05-04 | Evidence for FOXL2 Association with the Tsc1 Regulatory Region in Mice.

Ovarian reserve and reproductive life are closely linked concepts in female reproductive biology. The ovarian reserve consists of primordial follicles and refers to the number and quality of oocytes (eggs) remaining in the ovaries at any given time. Follicular dynamics shape a woman's reproductive lifespan, ultimately leading to menopause. Elucidating the underlying genetic and molecular pathways of follicle maturation and depletion is thus crucial for understanding menopausal onset and progression, both in normal and pathophysiological contexts, such as primary ovarian insufficiency, defined as menopause before the age of 40. A key factor in ovarian differentiation and fertility maintenance is FOXL2, a forkhead family transcription factor that plays a crucial role in follicle formation and development, ovarian maintenance, and sex determination. By employing a ChIP-Seq approach in mice, we identified a previously unreported binding of FOXL2 to a Tsc1 regulatory region. Our data, along with a thorough literature review, support the hypothesis that FOXL2-mediated activation of Tsc1 in granulosa cells can help maintain primordial follicles in a dormant state by suppressing mTORC1 signalling. Understanding the mechanisms behind ovarian reserve may lay the foundation for developing novel fertility preservation strategies, improving fertility treatment protocols and promoting in vitro activation of cryopreserved ovarian tissue to support folliculogenesis.

Open article ↗



2025-07-11 | Modulation of infiltrating CD206+ macrophages restricts progression of pulmonary lymphangioleiomyomatosis.

Lymphangioleiomyomatosis (LAM) is a low-grade neoplasm caused by the proliferation of tuberous sclerosis complex (TSC) 1- or TSC2-deficient LAM cells, resulting in progressive cystic lung disease. The currently approved treatment for LAM delays disease progression but the disease recurs if treatment is discontinued. Therefore, new therapeutic targets and/or strategies are necessary for a cure. Immunosuppressive M2-like macrophages are involved in the progression of various cancers, but their role in the pathophysiology of LAM and as a putative therapeutic target is unknown. To identify the different immune cell populations involved in LAM, we generated a single-cell transcriptomic map of pulmonary LAM. Interactions between macrophages and LAM cells were studied using the Visium spatial transcriptomic platform and immunofluorescence staining on human pulmonary LAM specimens. Direct co-culture models were used to characterise the influence of TSC2-deficient cells on macrophage differentiation. The efficacy of targeting M2-like macrophages was assessed in preclinical mouse models of TSC2-deficient subcutaneous tumours treated with RP-182, a synthetic peptide which reprogrammes macrophages towards an antitumour M1-like phenotype. Single-cell RNA-sequencing analysis revealed that the majority of macrophages in pulmonary LAM display immunosuppressive markers, including CD206/MRC1 and CD163. Spatial transcriptomic and immunofluorescence analyses showed that M2 macrophages are in close proximity to LAM cells and that LAM cells that are in close proximity to macrophages highly express macrophage-homing factor chemokine ligand CXCL12. In vitro, co-culture of human and mouse macrophages with TSC2-deficient cells resulted in the upregulation of M2-marker-expressing macrophages. Targeting M2 macrophages via treatment with the CD206 modulator RP-182 impaired the growth of TSC2-deficient tumours in vivo. LAM cells recruit and polarise macrophages towards an M2 phenotype. M2-like CD206high macrophages may represent a potential therapeutic target in LAM.

Open article ↗



2025-06-25 | Cell-cell communication dysregulation in tuberous sclerosis complex cortical tubers and focal cortical dysplasia

Malformations of cortical development are manifestations of mTORopathies, including tubers in context of Tuberous Sclerosis Complex (TSC) cortical tubers and Focal Cortical Dysplasia (FCD), and are associated with epilepsy, often accompanied by comorbidities such as autism spectrum disorder (ASD). This study aims to investigate the cell-type-specific transcriptional alterations and disrupted intercellular communication networks in mTORopathies, focusing on their implications for cortical network dysfunction. Using single-cell RNA sequencing, we identified 33 transcriptionally distinct cell clusters across control and pathological samples, including neuronal, glial, and endothelial populations. Our analysis revealed disease-specific changes, such as the loss of certain glutamatergic and microglial clusters in cortical tubers (TSC), MTOR_FCD and DEPDC5_FCD, and the presence of a unique endothelial cluster in pathological samples. Pathway enrichment analysis highlighted the critical role of synaptic signaling, axonogenesis, and neuroimmune regulation in these disorders. Additionally, cell-cell communication network analysis demonstrated disrupted interactions between neuron-astrocyte, astrocyte-OPC, and microglia-neuron across mTORopathies. We found that the neurexins-neuroligins (NRXN-NLGN) signaling pathway, crucial for synapse formation and stability, was altered in both glutamatergic and GABAergic neurons, reflecting dysregulated synaptic plasticity and impaired neuron-glia communication. These findings provide novel insights into the molecular underpinnings of mTORopathies and suggest potential therapeutic targets to restore cellular communication and synaptic function in these disorders.

Open article ↗



2025-02-12 | Ezrin defines TSC complex activation at endosomal compartments through EGFR-AKT signaling.

Endosomes have emerged as major signaling hubs where different internalized ligand-receptor complexes are integrated and the outcome of signaling pathways are organized to regulate the strength and specificity of signal transduction events. Ezrin, a major membrane-actin linker that assembles and coordinates macromolecular signaling complexes at membranes, has emerged recently as an important regulator of lysosomal function. Here, we report that endosomal-localized EGFR/Ezrin complex interacts with and triggers the inhibition of the Tuberous Sclerosis Complex (TSC complex) in response to EGF stimuli. This is regulated through activation of the AKT signaling pathway. Loss of Ezrin was not sufficient to repress TSC complex by EGF and culminated in translocation of TSC complex to lysosomes triggering suppression of mTORC1 signaling. Overexpression of constitutively active EZRINT567D is sufficient to relocalize TSC complex to the endosomes and reactivate mTORC1. Our findings identify EZRIN as a critical regulator of autophagy via TSC complex in response to EGF stimuli and establish the central role of early endosomal signaling in the regulation of mTORC1. Consistently, Medaka fish deficient for Ezrin exhibit defective endo-lysosomal pathway, attributable to the compromised EGFR/AKT signaling, ultimately leading to retinal degeneration. Our data identify a pivotal mechanism of endo-lysosomal signaling involving Ezrin and its associated EGFR/TSC complex, which are essential for retinal function.

Open article ↗



2025-01-23 | Brain-related sexual dimorphism in tuberous sclerosis complex: an overlooked matter.

Biological sex strongly impacts tuberous sclerosis complex (TSC) symptoms like epilepsy and autism. However, the mechanisms driving this influence remain largely unknown. Here, we discuss how sex-specific changes in brain synapses and neural networks may drive these differences, offering insights that could be crucial for developing targeted therapies for TSC.

Open article ↗



gene therapies
2026-08-27 | Antiseizure Medications in Development: Novel Mechanisms, Precision Therapy, and the Move Towards Disease Modification.

Background: Despite more than 30 licenced antiseizure medications (ASMs), approximately one third of people with epilepsy remain drug-resistant, and developmental and epileptic encephalopathies represent one of the greatest unmet needs in epilepsy therapeutics. The past decade has produced a substantial reorientation of ASM discovery, driven by epilepsy genetics, new disease models, advances in drug screening, and innovative therapeutic modalities. Objective: The objective of this study was to review the contemporary clinical-stage pipeline of ASMs with novel or differentiated mechanisms of action, organized by molecular target, while placing recent regulatory successes and instructive failures within the broader transition toward mechanism-based, precision, and potentially disease-modifying therapies. Findings: A 2024 pipeline analysis identified more than 200 epilepsy therapies in preclinical or clinical development; at the cutoff of the present literature search (30 June 2026), over 40 compounds had reached phase II or III, with the majority directed at DEEs. Functional-state-selective sodium channel modulation has emerged as a leading conceptual advance supported by converging mechanistic and early clinical evidence, exemplified by relutrigine (PRAX-562), a preferential persistent-current inhibitor for which a regulatory decision is pending in SCN2A/SCN8A-DEEs, and vormatrigine (PRAX-628), whose large open-label effect was not reproduced in a controlled (blinded) trial. Several of the efficacy figures summarized here derive from congress presentations, interim analyses, or open-label extensions and await full peer-reviewed publication. Parallel advances include the selective Kv7 opener azetukalner; the dual-mechanism benchmark cenobamate; cholesterol-24-hydroxylase inhibition (soticlestat); selective serotonergic agonism (bexicaserin); glutamatergic precision agents (radiprodil); subtype-selective GABAA modulators (darigabat, ganaxolone); and gene-directed therapies (zorevunersen, elsunersen). Pre-symptomatic intervention in tuberous sclerosis complex provides an early, single-trial clinical proof of principle for delaying and reducing the incidence of epilepsy in a genetically defined population; this should not yet be equated with established disease prevention. Conclusions: The pipeline reflects an ongoing shift from broad symptomatic agents toward mechanism-led, genotype-matched, and potentially disease-modifying treatments. This shift is tempered by a persistent translational gap between early signals and randomized-trial confirmation, and by the preliminary status of much of the supporting evidence.

Open article ↗



2026-07-24 | Case Report: Induction of labor and postpartum management for fetal cardiac rhabdomyoma: a genetic etiology-based analysis of three cases.

Fetal cardiac rhabdomyoma (CR) is a rare primary cardiac tumor often linked to tuberous sclerosis complex (TSC) caused by TSC1/TSC2 mutations, yet its genetic heterogeneity and individualized perinatal management remain incompletely defined. This case series reports three primigravid women with fetuses diagnosed with CR at different gestational ages, who received induced labor via various regimens. Genetic testing identified a paternally inherited TSC2 mutation in one case, a de novo TSC1 mutation in another, while genetic analysis was declined in the third. Distinct differences exist in recurrence risk, long-term neurological prognosis and corresponding clinical decision-making between de novo TSC1 variants and paternally inherited TSC2 mutations, which fully reflects prominent genetic heterogeneity among TSC-related fetal CR. This study demonstrates the clinical and genetic heterogeneity of fetal CR, and highlights that ultrasound evaluation, TSC1/TSC2 genetic testing, and multidisciplinary care are crucial for guiding induction timing, perinatal management, and genetic counseling to improve perinatal outcomes.

Open article ↗



2026-03-09 | Neurogenetic tumor syndromes: The current landscape of workup and treatment.

Experts and generalists from numerous clinical disciplines are likely to encounter and be involved in the care of patients with neurogenetic tumor syndromes. Considerations for genetic testing are discussed. Specific conditions including neurofibromatosis type 1, neurofibromatosis type 2-related schwannomatosis, von Hippel-Lindau disease, tuberous sclerosis, Lynch syndrome, Turcot syndrome, Li-Fraumeni syndrome, and others are reviewed. A variety of targeted therapies which have received regulatory approval for these disorders are described and promising future directions for therapeutics are highlighted.

Open article ↗



2025-12-08 | Cerebellar tubers in tuberous sclerosis complex: MRI characteristics and longitudinal evolution in a pediatric and young adult cohort

Abstract Background Tuberous sclerosis complex (TSC) is a multisystem genetic disorder characterized by the development of benign tumors across multiple organ systems. While supratentorial cerebral manifestations are well documented, infratentorial involvement, particularly cerebellar tubers, remains less explored. This study aimed to evaluate the prevalence, imaging characteristics, and longitudinal changes of cerebellar tubers in patients with TSC. Methods A retrospective analysis was conducted on 61 pediatric and young adult patients diagnosed with TSC who underwent brain MRI between 2005 and 2023. MR imaging included standard sequences such as T1WI, T2WI, FLAIR, DWI, ADC mapping, SWI, and post-contrast T1WI. All scans were independently reviewed by three experienced neuroradiologists (each one with 15 years of experience); they were blinded to clinical data. Results Cerebellar tubers were identified in 29 out of 61 patients (47.5%), totaling 50 lesions. The most common morphology was wedge-shaped (96%). Signal intensity varied across sequences: T1 hypointense (92%), T2 hyperintense (86%), and FLAIR mixed patterns (variable). Enhancement after contrast administration was observed in 6% of tubers (striated pattern), and calcifications were present in 14%. Retraction deformities adjacent to tubers were noted in 48% of cases. Patients with cerebellar tubers had significantly more cerebral tubers than those without (mean: 29 vs 22; p < 0.001). Follow-up MRI in 13 patients (mean follow-up: 5.3 years) showed stability in 84.6%, slight regression in 7.7%, and progression in 7.7%. Conclusions Cerebellar tubers are relatively common in TSC and exhibit distinct morphological and signal characteristics. These lesions demonstrate dynamic behavior over time, correlating with supratentorial abnormalities and potentially influencing neurobehavioral outcomes. Awareness of these features can aid in early diagnosis and long-term monitoring.

Open article ↗



2025-12-03 | Renal epithelioid angiomyolipoma: A multi-institutional, international cohort study with emphasis on clinicopathologic prognostic indicators.

Renal angiomyolipoma (AML) is a benign perivascular epithelioid cell neoplasm that is often associated with tuberous sclerosis complex (TSC). Epithelioid AML (eAML), a very rare and potentially malignant variant, can be challenging to radiologically differentiate from benign AML and other renal tumors. Adverse histological features have previously been associated to poorer oncological outcomes. This study aimed to characterize this rare disease entity and validate previously reported adverse prognostic factors. This multicenter, retrospective cohort study analyzed 76 patients diagnosed with eAML between 2001 and 2024 across 15 participating centers. Inclusion criteria were histological diagnosis of eAML with negative cytokeratin markers and positive melanocytic markers. Patients were stratified according to previously described adverse pathological features. A total of 76 patients were studied. Most were female (70%), with a median age of 48 years and, 19 patients had TSC. Median tumor size was 45 mm, with a rate of atypical epithelioid cells >70% in 26 (34.2%) patients. According to the Nese's and Brimo's classifications, 4% and 14% of patients were at high risk, respectively. During a median follow- up of 30-months, 5 (6.7 %) patients developed metastases, and 4 (5.3 %) died. At univariable analysis, the number of adverse pathological risk factors, according to both classifications, was significantly associated with worse metastasis free survival (MFS) and cancer specific survival (CSS). Due to the low number of events, a multivariable analysis was not carried out. eAML is extremely rare, and primarily affects middle-aged women. This cohort validated previously described pathological risk factors for worse prognosis, suggesting that patients with multiple adverse features may require more intensive follow-up.

Open article ↗



oligonucleotides
2024-10-16 | Subependymal Giant Cell Astrocytoma: The Molecular Landscape and Treatment Advances.

Subependymal giant cell astrocytoma (SEGA) is most often found in patients with TSC (Tuberous Sclerosis Complex). Although it has been classified as a benign tumor, it may create a serious medical problem leading to grave consequences, including young patient demise. Surgery and chemotherapy belong to the gold standard of treatment. A broader pharmacological approach involves the ever-growing number of rapalogs and ATP-competitive inhibitors, as well as compounds targeting other kinases, such as dual PI3K/mTOR inhibitors and CK2 kinase inhibitors. Novel approaches may utilize noncoding RNA-based therapeutics and are extensively investigated to this end. The purpose of our review was to characterize SEGA and discuss the latest trends in the diagnosis and therapy of this disease.

Open article ↗



2024-08-23 | miR-25-5p in exosomes derived from UVB-induced fibroblasts regulates melanogenesis via TSC2-dominated cellular organelle dysfunction.

Few reports have confirmed whether exosomes derived from fibroblasts can regulate the process of melanogenesis. We wondered whether exosomes derived from fibroblasts could have a potent regulatory effect on melanogenesis and explored the underlying mechanisms. This study aimed to find the role of fibroblasts in melanocytes and revealed the related mechanisms. RT-qPCR, Western blot analysis were conducted to measure the RNA and protein expression level of various related genes. miRNA sequencing, mass spectrum analysis and subsequent bioinformatics analysis were employed to find the underlying targets. Zebrafish were employed to measure the melanin synthesis related process in vivo. Furthermore, electron microscopy, ROS measurement and dual-luciferase reporter assay were adopted to investigate the relationship between these processes. We found that exosomes derived from human primary dermal fibroblasts were internalized by human primary melanocytes and MNT1 cells and that the melanin content and the expression of melanin synthesis-related proteins TYR and MITF was inhibited by exosomes derived from UVB-induced human primary dermal fibroblasts. The miRNA expression profile in secreted exosomes changed significantly, with miR-25-5p identified as capable of regulating TSC2 expression via the CDS region. The miR-25-5p-TSC2 axis could affect the melanin content through subsequent cellular organelle dysfunction, such as mitochondrial dysfunction, endoplasmic reticulum stress and dysregulation of lysosomal cysteine proteases. We unveiled a novel regulatory role of fibroblasts in melanocytes, facilitated by the secretion of exosomes. miR-25-5p within exosomes plays a pivotal role in regulating melanogenesis via TSC2-induced cellular organelle dysfunction.

Open article ↗



2023-04-03 | MicroRNA Expression Profile in TSC Cell Lines and the Impact of mTOR Inhibitor.

The aim of this study was to assess the potential implication of microRNA on tuberous sclerosis (TSC) pathogenesis by performing microRNA profiling on cell lines silencing TSC1 or TSC2 genes using qPCR panels, before and after incubation with rapamycin. Significant differences in expression were observed between samples before and after rapamycin treatment in nineteen miRNAs in TSC1, five miRNAs in TSC2 and seven miRNAs in controls. Of miRNAs dysregulated before rapamycin treatment, three normalized after treatment in the TSC1 group (miR-21-3p, miR-433-3p, let-7g-3p) and one normalized in the TSC2 group (miR-1224-3p). Of the miRNAs dysregulated before rapamycin treatment in the TSC1 and TSC2 groups, two did not normalize after treatment (miR-33a-3p, miR-29a-3p). The results of the possible targets indicated that there are four common genes with seed regions susceptible to regulation by those miRNAs: ZBTB20, PHACTR2, PLXNC1 and ATP1B4. Our data show no changes in mRNA expression of these targets after rapamycin treatment. In conclusion, results of our study indicate the involvement of miRNA dysregulation in the pathogenesis of TSC. Some of the miRNA might be used as markers of treatment efficacy and autonomic miRNA as a target for future therapy.

Open article ↗



2022-10-27 | Extracellular vesicles derived from endometrial epithelial cells deliver exogenous miR-92b-3p to affect the function of embryonic trophoblast cells via targeting TSC1 and DKK3.

Extracellular vesicles (EVs) could mediate embryo-maternal communication to affect embryo implantation by delivering biology information, including microRNA (miRNA), protein, lipid. Our previous research shows that miR-92b-3p was differentially expressed in EVs of uterine flushing fluids during the embryo implantation period. However, the role of miR-92b-3p from EVs in embryo implantation remains elusive. EVs were isolated from porcine endometrial epithelial cells (EECs) by ultracentrifugation. MiR-92b-3p mimics and EVs were used to regulate the expression of miR-92b-3p in porcine trophoblast cells (PTr2 cells). Cell proliferation, migration and adhesion analyses were used to observe the phenotype. RT-qPCR, western blot and dual-luciferase reporter assay were used to assess the targets of miR-92b-3p. In this study, EVs derived from porcine EECs were identified and could be taken up by PTr2 cells. We found that the EVs derived from EECs transfected with miR-92b-3p mimic (EVs-miR-92b-3p) significantly promoted the proliferation, migration and adhesion of PTr2 cells. We verified that Tuberous sclerosis complex subunit (TSC1) and Dickkopf 3 (DKK3) were the target genes of miR-92b-3p. Moreover, our study showed that miR-92b-3p plays a vital role in PTr2 cells via targeting TSC1 and DKK3. Furthermore, the 3'UTR vectors of TSC1 and DKK3 can rescue the effect of miR-92b-3p on PTr2 cells. Taken together, this study reveals a novel mechanism that EVs derived from porcine EECs treated with miR-92b-3p crosstalk with trophoblasts by targeting TSC1 and DKK3, leading to an enhanced ability for implantation.

Open article ↗



2022-04-12 | Peripheral Serum Exosomes Isolated from Patients with Acute Myocardial Infarction Promote Endothelial Cell Angiogenesis via the miR-126-3p/TSC1/mTORC1/HIF-1α Pathway.

Angiogenesis is required for improving myocardial function and is a key factor in long-term prognosis after an acute myocardial infarction (AMI). Although exosomes are known to play a crucial role in angiogenesis, the role of peripheral exosomes in angiogenic signal transduction in patients with AMI remains unclear. Here, we explored the effect of exosomes extracted from the peripheral serum of AMI patients on angiogenesis and elucidated the downstream pathways. Serum exosomes were obtained from patients with AMI (AMI-Exo) and healthy individuals (Con-Exo). The exosomes were cocultured with human umbilical vein endothelial cells (HUVECs) in vitro, with aortic rings ex vivo, and were used to treat mouse hind-limb ischemia and mouse AMI model in vivo. AMI-Exo raised HUVEC proliferation, tube formation, and migration, and enhanced microvessel sprouting from aortic rings compared to Con-Exo, both in vitro and ex vivo. Quantitative reverse transcription-polymerase chain reaction revealed that the abundance of miR-126-3p, a crucial regulator of angiogenesis, was increased in AMI-Exo. The inhibition of miR-126-3p decreased the benefits of AMI-Exo treatment, and miR-126-3p upregulation enhanced the benefits of Con-Exo treatment in HUVECs, aortic rings, the mouse hind-limb ischemia model, and the mouse AMI model. Knockdown and overexpression analyses revealed that miR-126-3p regulated angiogenesis in HUVECs by directly targeting tuberous sclerosis complex 1 (TSC1). Moreover, we found that miR-126-3p could inhibit TSC1 expression, which further activated mTORC1 signaling and increased HIF-1α and VEGFA expression, ultimately promoting angiogenesis. Collectively, our results provide a novel understanding of the function of exosomes in angiogenesis post AMI. We demonstrated that exosomes from the peripheral serum of AMI patients promote angiogenesis via the miR-126-3p/TSC1/mTORC1/HIF-1α signaling pathway.

Open article ↗



other
2026-09-24 | mTORC1 drives cell-autonomous astrocyte reactivity in tuberous sclerosis.

Tuberous sclerosis complex (TSC) is a genetic neurodevelopmental disorder characterized by focal brain malformations called cortical tubers, which are associated with severe, intractable epilepsy1. Tubers are thought to result from somatic second-hit mutations that disrupt the TSC1 or TSC2 genes in neural progenitor cells, driving hyperactive mTORC1 signalling2. Glial abnormalities are commonly observed in tubers3; however, whether glia actively cause disease or merely result from chronic seizure activity has remained unclear. To address this question, we used human brain organoid models to track the developmental fate of mutated progenitor cells in the absence of seizures. Here we show, using single-cell transcriptomics and cyclic immunostaining across human brain organoids and resected tuber tissue from patients, that loss of TSC2 biases neural progenitors to differentiate into enlarged, pro-inflammatory reactive astrocytes in a cell autonomous manner. These mutant astrocytes show downregulated glutamate transporter expression, increased inflammatory cytokine secretion and elevated expression of neurodegenerative disease risk genes such as APOE and CLU. Our findings demonstrate that reactive astrocytes emerge as a primary consequence of TSC2 loss. These results implicate glial dysfunction as a driver of TSC pathogenesis and highlight reactive astrocytes as potential therapeutic targets for TSC-related neuropathology.

Open article ↗



2026-09-19 | Unilateral Fibrovascular Vitreoretinal Proliferation Associated With Retinal Astrocytic Hamartoma Revealing Tuberous Sclerosis Complex in Adulthood.

To report an unusual presentation of previously undiagnosed tuberous sclerosis complex manifesting as unilateral fibrovascular vitreoretinal proliferation associated with retinal astrocytic hamartoma complicated by vitreous hemorrhage (VH). A single case was reviewed. A 29-year-old woman presented with visual loss in the left eye and longstanding reduced vision since childhood. Examination revealed a retinal astrocytic hamartoma in the right eye and VH, fibrovascular vitreoretinal proliferation, retinal disorganization, and macular thickening in the left eye. Fluorescein angiography demonstrated telangiectatic vessels and late-phase leakage. The presence of accompanying cutaneous lesions prompted multidisciplinary evaluation, which revealed systemic tuberous sclerosis complex associated with a heterozygous TSC1 mutation. Following a single intravitreal injection of bevacizumab, regression of the VH and stabilization of the proliferative retinal findings were observed during 1 year of follow-up. Retinal astrocytic hamartomas associated with tuberous sclerosis complex are generally benign and asymptomatic; however, rare progressive forms may present with fibrovascular vitreoretinal proliferative complications. Ocular manifestations may play a critical role in diagnosing previously unrecognized tuberous sclerosis complex.

Open article ↗



2026-07-21 | mTORC1 activation induces B7-H3-dependent metabolic reprogramming in renal cell carcinoma (RCC).

Renal cell carcinoma (RCC) affects over 435,000 people worldwide each year and remains a significant cause of cancer mortality. Aberrant activation of pathways such as mTORC1 is frequently observed in RCC, yet the mechanisms by which mTORC1 contributes to tumor development remain poorly understood. The lack of suitable animal models has limited progress in uncovering these mechanisms and advancing targeted treatments. Here, we performed single-cell transcriptomic, proteomic, and metabolomic profiling of kidneys from mice with embryonic Tsc2 deletion at E17.5, which revealed a distinct tumor cell population characterized by intercalated cell signatures, co-expression of Foxi1 and Rhcg, and hyperactivated mTORC1. These lesions closely resemble human chromophobe renal cell carcinoma (ChRCC), a subtype of RCC. The tumors show marked upregulation of the immune checkpoint molecule B7-H3. Mechanistically, the transcription factor NRF1 is elevated in Tsc2-deficient lesions and drives B7-H3 expression in tumor cells. In human specimens, B7-H3 is broadly expressed in both classical and sarcomatoid ChRCC and correlates with hallmark markers FOXI1, MUC2, and HEPACAM2. Strikingly, B7-H3 deletion in mice suppresses Tsc2 loss-driven cystic and tumor formation, restores amino acid metabolism, and attenuates aminoacyl-tRNA biosynthesis and proteasome activity. Collectively, these findings identify B7-H3 as a functional driver of Tsc2-mediated ChRCC and a promising therapeutic target in TSC-associated renal tumors.

Open article ↗



2026-07-17 | GPR143, a novel immunohistochemical marker for renal tumors with FLCN/TSC/MTOR-TFE alterations.

Although several ancillary tests are available in limited laboratories, diagnosis of microphthalmia (MiT)/TFE family translocation renal cell carcinoma (tRCC) could be challenging due to diverse and overlapping tumor morphology and the lack of reliable biomarkers. GPNMB has been recently identified as a diagnostic marker for various renal neoplasms with FLCN/TSC/mTOR-TFE alterations. However, the sensitivity and specificity of GPNMB immunostain are suboptimal and the result interpretation in ambiguous cases could be difficult. To search additional biomarkers that could improve the screening sensitivity and predict genetic aberrations in FLCN/TSC/mTOR-TFE pathway in renal tumors, we performed bioinformatic analysis of publicly available cancer databases and found GPR143, a transmembrane protein regulated by MiT transcription factors, was highly expressed in a subset of renal cell carcinomas (RCCs). In two kidney cancer cohorts of the Cancer Genome Atlas (TCGA), RCCs with high levels of GPR143 expression were enriched for renal neoplasms with FLCN/TSC/mTOR-TFE alterations. Similar to GPNMB labeling, GPR143 immunostain was positive in the majority of tRCC cases and renal tumors with FLCN/TSC/mTOR alterations, suggesting that GPR143 could function as another surrogate marker for FLCN/TSC/mTOR-TFE alterations in certain renal tumors. Interestingly, despite the concordant GPR143 and GPNMB immunoreactivity in most renal neoplasms with FLCN/TSC/mTOR-TFE alterations, diffuse GPR143 immunostain was observed in some cases with negative or focal GPNMB labeling. Taken together, our results indicate GPR143 could serve as a useful adjunct marker to improve the sensitivity for screening renal tumors with FLCN/TSC/mTOR-TFE alterations.

Open article ↗



2026-05-31 | Long-term outcomes of selective arterial embolization in giant renal angiomyolipoma: A retrospective single-center study.

To evaluate the long-term outcomes of selective trans-arterial embolization (SAE) in patients with giant (⩾10 cm in size) renal angiomyolipomas (AMLs) at our tertiary referral center. This retrospective, single-center study included 44 patients who underwent SAE for AMLs of ⩾10 cm size between July 2018 and June 2024. Collected data included demographics, tumor characteristics, clinical symptoms, type of intervention, tumor size before and after embolization, and renal function. Outcomes assessed were tumor size reduction, preservation of renal function, reintervention rates during follow-up and complications following SAE. The study included 46 tumors in 44 patients. Mean patient age was 40.4 years (range: 23-60), with 86.3% being females. Mean follow-up duration was 25.2 months (range: 6-70 months). Eleven patients (25%) were associated with TSC, and all were offered Everolimus postoperatively. The mean tumor size decreased significantly from 13.2 ± 3.12 cm pre-embolization to 10.3 ± 2.45 cm post-embolization (p = 0.003). Renal function remained stable during follow-up, with no significant changes in serum creatinine (p = 0.6) and eGFR (p = 0.8). The overall success rate was 84.7%, with 13.6% experiencing re-intervention. Complications included post-embolization syndrome (43.1%) and allergic reactions (6.8%), while one patient required nephrectomy due to a perinephric abscess. Selective Trans-arterial Embolization is a safe and effective treatment for giant renal AMLs, resulting in significant tumor size reduction, symptom relief, and preservation of renal function. It offers a minimally invasive alternative to traditional surgical approaches, particularly for patients with high surgical risk or those requiring nephron-sparing procedure.

Open article ↗



small molecules
2026-09-30 | Hepatic PEComas ‒ A national multicenter study. Clinical, pathological, and surgical outcomes.

PEComas are neoplasms originating from perivascular epithelioid cells. Their incidence is higher in patients with tuberous sclerosis; however, hepatic PEComas are exceptionally rare compared to those in other locations. Diagnostic confirmation relies on histopathological findings and immunohistochemical phenotypes. To evaluate the clinical-radiological presentation, histopathological characteristics, and surgical outcomes of a multicenter cohort of hepatic PEComas. A retrospective, multicenter, nationwide observational study of patients with histologically confirmed hepatic PEComa who underwent surgery at Spanish centers between 2010 and 2024. Twenty-two patients were included; 21 (95.5%) were women, with a mean age of 54.7 years. Mean tumor size was 4.3 cm. Preoperative radiological diagnosis was challenging, with PEComa identified in only one case (4.5%). Preoperative biopsy was performed in 8 patients, yielding a diagnosis of PEComa in 6 cases (75%). Surgical procedures consisted of minor hepatectomy in 14 patients (63.6%) and major hepatectomy in 8 patients (36.4%). The 90-day mortality rate was 0%. Mean hospital stay was 4.5 days. Immunohistochemical analysis was positive for: HMB45 (19 patients, 90.5%), Melan-A (17, 81%), and actin (13, 61.9%). After a median follow-up of 49 months, no recurrences were detected. Preoperative diagnosis of PEComa poses a radiological challenge, frequently requiring biopsy for confirmation. Surgical treatment was not associated with mortality, showed a relevant complication rate of 18.2%, and no recurrences were observed.

Open article ↗



2026-09-21 | Case Report: Presymptomatic risdiplam in preterm monozygotic twins with co-occurring spinal muscular atrophy and tuberous sclerosis complex.

Spinal muscular atrophy (SMA) and tuberous sclerosis complex (TSC) are both rare genetic disorders, and their co-occurrence is expected to be exceptionally uncommon. Although risdiplam has demonstrated efficacy in SMA, evidence regarding its use in preterm infants with complex genetic comorbidities remains limited. We report preterm monozygotic twins born at 32+5 weeks of gestation with genetically confirmed SMA caused by homozygous deletion of SMN1 exons 7-8, with two copies of SMN2. During baseline evaluation prior to presymptomatic treatment, brain magnetic resonance imaging revealed incidental abnormalities, including cortical dysplasia and subependymal nodules, which prompted further genetic testing and led to the diagnosis of TSC with a TSC1 c.1041G>A variant. Presymptomatic risdiplam was initiated at a corrected gestational age of 38+5 weeks. Both twins showed marked improvement in motor function. By 12 months of age, they had achieved independent rolling, unsupported sitting, crawling, and pulling to stand, accompanied by substantial improvements in CHOP INTEND and HINE-2 scores. Risdiplam was well tolerated, and no commonly reported adverse events were observed during follow-up. This report describes the first documented co-occurrence of SMA and TSC in preterm monozygotic twins and suggests that presymptomatic risdiplam may be effective and well tolerated in this complex clinical setting over 1 year of follow-up. These findings also highlight the importance of comprehensive genetic evaluation in infants with SMA who present with atypical neuroimaging or neurological features. Longer-term follow-up is needed to clarify safety, efficacy, and optimal integrated management strategies in patients with complex genetic comorbidities.

Open article ↗



2026-09-21 | Effectiveness and safety of cannabidiol in adult patients with epilepsy: A multicenter, retrospective study.

Cannabidiol (CBD) has demonstrated promising effectiveness and tolerability as adjunctive treatment in patients with severe childhood epilepsies. This study investigated the effectiveness and tolerability of CBD in adults with a history of Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC). This was a multicenter, retrospective, observational study in adults with diagnosis of DS, LGS or TSC who received at least 12 months of CBD treatment. Medical records were reviewed and baseline characteristics, treatment retention, seizure frequency, cognitive behavioral improvements, concomitant ASM usage, and adverse events were assessed. Thirty-seven patients (median age 25 years; 67.5% male) with diagnosis of DS, LGS or TSC received CBD for at least 12 months. The CBD median maintenance dose was 10.45 mg/kg/day (IQR 7.455 - 13.975) (median maximum dose 11 mg/kg/day); median follow-up time was 28 months (IQR 22.75-58.25). Seizure frequency was reduced by ≥50% in 48.6% of patients at 6 months and 45.9% at 12 months. No statistically significant differences in median maintenance dose were observed across seizure reduction categories. During CBD treatment, caregivers reported subjective improvements in cognition in 29.7% of patients. Treatment with CBD was significantly associated with a reduction in the median number of concomitant ASMs at the end of follow-up (4 [3, 4]) vs. 3 [3, 4] (p = 0.022). AEs occurred in 64.9% of patients and were mostly mild; 16.2% had AEs leading to treatment discontinuation. We present a series of adult patients treated with CBD according to label. The results are similar to those described in children. CBD treatment was associated with clinically meaningful seizure reduction and acceptable tolerability in this real-world cohort of adults with drug-resistant developmental and epileptic encephalopathies. These findings support the potential role of CBD in complex adult DEE populations while highlighting the need for prospective controlled studies to better define its independent treatment effect. This study looked at the long-term use of cannabidiol (CBD) in 37 adults with Dravet syndrome, Lennox-Gastaut syndrome, or tuberous sclerosis complex. After 12 months, almost half of the patients had at least a 50% reduction in seizures. Some caregivers also reported improvements in cognition and behavior. Patients were able to reduce the number of other antiseizure medicines they were taking. Side effects were common but mostly mild, although a small number of patients stopped treatment because of them. Overall, CBD appeared effective and reasonably well tolerated, but further controlled studies are needed.

Open article ↗



2026-09-19 | Tryptophan-enriched diet improves social behavior in a mouse model of tuberous sclerosis complex.

Background: Tryptophan is an essential dietary amino acid and the sole precursor of serotonin (5-HT), a neurotransmitter that plays a key role in cognition, mood regulation, and sensory processing. Because central serotonin synthesis depends on dietary tryptophan availability, nutritional modulation of tryptophan intake has emerged as a potential strategy to influence brain function and behavior. Disruptions in tryptophan metabolism and serotonergic signaling have been implicated in autism spectrum disorder (ASD), particularly in Tuberous Sclerosis Complex (TSC), a neurogenetic condition frequently associated with ASD. In this study, we investigated whether dietary tryptophan supplementation could modulate brain tryptophan metabolism and improve ASD-related behaviors in the Tsc2+/- mouse model. Methods: For that, behavioral tests were performed together with in vivo magnetic resonance spetrosocopy (1H-MRS) and ex vivo high-performance liquid chromatography (HPLC). Results: Behavioral analysis revealed sex-specific improvements following supplementation, including enhanced sociability in females, restoration of social novelty preference in males, and reduced anxiety-like behavior accompanied by increased exploratory activity across groups. These behavioral changes were associated with increased cortical tryptophan levels, as determined by high-performance liquid chromatography. However, no significant alterations in cortical excitation/inhibition balance were detected using in vivo proton magnetic resonance spectroscopy. Conclusions: Together, these findings demonstrate that dietary tryptophan supplementation enhances cortical tryptophan availability and ameliorates ASD-like behavioral phenotypes in Tsc2+/- mice. Our results highlight the potential of nutritional modulation of tryptophan intake as a non-invasive strategy to influence serotonergic pathways and behavioral outcomes, supporting the development of precision nutrition approaches for neurodevelopmental disorders.

Open article ↗



2026-09-17 | Use of Purified Cannabidiol in Treatment-Resistant Pediatric Epilepsy: Beyond Lennox-Gastaut Syndrome, Dravet Syndrome, and Tuberous Sclerosis Complex.

The pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex) is approved by the the US Food and Drug Administration for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis in patients one year of age and older. Among the large volume of drug-resistant cases treated at pediatric Level 4 Epilepsy Centers, many patients fall outside of these categories but are still prescribed CBD for off label use. This study sought to characterize the real-world experience with CBD of a large single pediatric comprehensive epilepsy center and to compare response to CBD within and outside of its FDA-approved indications. A retrospective chart review was performed of patients with a prescription for CBD at our institution between January 2020 and January 2022, excluding patients who were previously included in our center's 2019 analysis. Patients were not included in the analysis if initially prescribed CBD elsewhere, follow-up was outside our institution, medication was not started, patient expired during the study period, or diagnostic data was not available. Between-group differences were assessed via Wilcoxon rank-sum and Fisher exact tests, as appropriate. Of 223 patients with a CBD prescription during the study period, 144 patients had sufficient data available for review. Of these patients, 81 (56%) carried diagnoses of Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis, and 63 (44%) carried other diagnoses outside of FDA-labeled indications. Median (interquartile range) age at initiation was 10.0 years (5.0, 13.0), and median (interquartile range) number of concurrent anti-seizure medications was 3.0 (2.0, 3.0). There was no significant difference in the proportion of patients treated concurrently with vagus nerve stimulation or ketogenic diet between the two groups. The FDA-labeled (63%) group had a significantly higher proportion of patients with tonic seizures compared to the non-FDA labeled (29%) group (P < 0.001), otherwise there were no significant differences in baseline seizure types. Overall, 53 patients (65%) in the FDA-labeled group and 40 (63%) of the non-FDA labeled group had a documented responder rate at least 50% on CBD (P = 0.9). The most common side effects reported were nausea/diarrhea/gastrointestinal upset (19%), agitation (7.6%), insomnia (4.9%), weight loss (6.3%), and secretions/drooling (2.8%, seen only in patients on concurrent clobazam). Among our cohort of treatment-resistant pediatric epilepsy, purified CBD was efficacious in a broad range of pediatric epilepsies and was well tolerated as an adjunctive anti-seizure medication. This medication may be considered in pharmacoresistant pediatric epilepsies in conditions beyond its FDA-labeled indications.

Open article ↗



proteins
2026-05-04 | Evidence for FOXL2 Association with the Tsc1 Regulatory Region in Mice.

Ovarian reserve and reproductive life are closely linked concepts in female reproductive biology. The ovarian reserve consists of primordial follicles and refers to the number and quality of oocytes (eggs) remaining in the ovaries at any given time. Follicular dynamics shape a woman's reproductive lifespan, ultimately leading to menopause. Elucidating the underlying genetic and molecular pathways of follicle maturation and depletion is thus crucial for understanding menopausal onset and progression, both in normal and pathophysiological contexts, such as primary ovarian insufficiency, defined as menopause before the age of 40. A key factor in ovarian differentiation and fertility maintenance is FOXL2, a forkhead family transcription factor that plays a crucial role in follicle formation and development, ovarian maintenance, and sex determination. By employing a ChIP-Seq approach in mice, we identified a previously unreported binding of FOXL2 to a Tsc1 regulatory region. Our data, along with a thorough literature review, support the hypothesis that FOXL2-mediated activation of Tsc1 in granulosa cells can help maintain primordial follicles in a dormant state by suppressing mTORC1 signalling. Understanding the mechanisms behind ovarian reserve may lay the foundation for developing novel fertility preservation strategies, improving fertility treatment protocols and promoting in vitro activation of cryopreserved ovarian tissue to support folliculogenesis.

Open article ↗



2025-07-11 | Modulation of infiltrating CD206+ macrophages restricts progression of pulmonary lymphangioleiomyomatosis.

Lymphangioleiomyomatosis (LAM) is a low-grade neoplasm caused by the proliferation of tuberous sclerosis complex (TSC) 1- or TSC2-deficient LAM cells, resulting in progressive cystic lung disease. The currently approved treatment for LAM delays disease progression but the disease recurs if treatment is discontinued. Therefore, new therapeutic targets and/or strategies are necessary for a cure. Immunosuppressive M2-like macrophages are involved in the progression of various cancers, but their role in the pathophysiology of LAM and as a putative therapeutic target is unknown. To identify the different immune cell populations involved in LAM, we generated a single-cell transcriptomic map of pulmonary LAM. Interactions between macrophages and LAM cells were studied using the Visium spatial transcriptomic platform and immunofluorescence staining on human pulmonary LAM specimens. Direct co-culture models were used to characterise the influence of TSC2-deficient cells on macrophage differentiation. The efficacy of targeting M2-like macrophages was assessed in preclinical mouse models of TSC2-deficient subcutaneous tumours treated with RP-182, a synthetic peptide which reprogrammes macrophages towards an antitumour M1-like phenotype. Single-cell RNA-sequencing analysis revealed that the majority of macrophages in pulmonary LAM display immunosuppressive markers, including CD206/MRC1 and CD163. Spatial transcriptomic and immunofluorescence analyses showed that M2 macrophages are in close proximity to LAM cells and that LAM cells that are in close proximity to macrophages highly express macrophage-homing factor chemokine ligand CXCL12. In vitro, co-culture of human and mouse macrophages with TSC2-deficient cells resulted in the upregulation of M2-marker-expressing macrophages. Targeting M2 macrophages via treatment with the CD206 modulator RP-182 impaired the growth of TSC2-deficient tumours in vivo. LAM cells recruit and polarise macrophages towards an M2 phenotype. M2-like CD206high macrophages may represent a potential therapeutic target in LAM.

Open article ↗



2025-06-25 | Cell-cell communication dysregulation in tuberous sclerosis complex cortical tubers and focal cortical dysplasia

Malformations of cortical development are manifestations of mTORopathies, including tubers in context of Tuberous Sclerosis Complex (TSC) cortical tubers and Focal Cortical Dysplasia (FCD), and are associated with epilepsy, often accompanied by comorbidities such as autism spectrum disorder (ASD). This study aims to investigate the cell-type-specific transcriptional alterations and disrupted intercellular communication networks in mTORopathies, focusing on their implications for cortical network dysfunction. Using single-cell RNA sequencing, we identified 33 transcriptionally distinct cell clusters across control and pathological samples, including neuronal, glial, and endothelial populations. Our analysis revealed disease-specific changes, such as the loss of certain glutamatergic and microglial clusters in cortical tubers (TSC), MTOR_FCD and DEPDC5_FCD, and the presence of a unique endothelial cluster in pathological samples. Pathway enrichment analysis highlighted the critical role of synaptic signaling, axonogenesis, and neuroimmune regulation in these disorders. Additionally, cell-cell communication network analysis demonstrated disrupted interactions between neuron-astrocyte, astrocyte-OPC, and microglia-neuron across mTORopathies. We found that the neurexins-neuroligins (NRXN-NLGN) signaling pathway, crucial for synapse formation and stability, was altered in both glutamatergic and GABAergic neurons, reflecting dysregulated synaptic plasticity and impaired neuron-glia communication. These findings provide novel insights into the molecular underpinnings of mTORopathies and suggest potential therapeutic targets to restore cellular communication and synaptic function in these disorders.

Open article ↗



2025-02-12 | Ezrin defines TSC complex activation at endosomal compartments through EGFR-AKT signaling.

Endosomes have emerged as major signaling hubs where different internalized ligand-receptor complexes are integrated and the outcome of signaling pathways are organized to regulate the strength and specificity of signal transduction events. Ezrin, a major membrane-actin linker that assembles and coordinates macromolecular signaling complexes at membranes, has emerged recently as an important regulator of lysosomal function. Here, we report that endosomal-localized EGFR/Ezrin complex interacts with and triggers the inhibition of the Tuberous Sclerosis Complex (TSC complex) in response to EGF stimuli. This is regulated through activation of the AKT signaling pathway. Loss of Ezrin was not sufficient to repress TSC complex by EGF and culminated in translocation of TSC complex to lysosomes triggering suppression of mTORC1 signaling. Overexpression of constitutively active EZRINT567D is sufficient to relocalize TSC complex to the endosomes and reactivate mTORC1. Our findings identify EZRIN as a critical regulator of autophagy via TSC complex in response to EGF stimuli and establish the central role of early endosomal signaling in the regulation of mTORC1. Consistently, Medaka fish deficient for Ezrin exhibit defective endo-lysosomal pathway, attributable to the compromised EGFR/AKT signaling, ultimately leading to retinal degeneration. Our data identify a pivotal mechanism of endo-lysosomal signaling involving Ezrin and its associated EGFR/TSC complex, which are essential for retinal function.

Open article ↗



2025-01-23 | Brain-related sexual dimorphism in tuberous sclerosis complex: an overlooked matter.

Biological sex strongly impacts tuberous sclerosis complex (TSC) symptoms like epilepsy and autism. However, the mechanisms driving this influence remain largely unknown. Here, we discuss how sex-specific changes in brain synapses and neural networks may drive these differences, offering insights that could be crucial for developing targeted therapies for TSC.

Open article ↗



gene therapies
2026-08-27 | Antiseizure Medications in Development: Novel Mechanisms, Precision Therapy, and the Move Towards Disease Modification.

Background: Despite more than 30 licenced antiseizure medications (ASMs), approximately one third of people with epilepsy remain drug-resistant, and developmental and epileptic encephalopathies represent one of the greatest unmet needs in epilepsy therapeutics. The past decade has produced a substantial reorientation of ASM discovery, driven by epilepsy genetics, new disease models, advances in drug screening, and innovative therapeutic modalities. Objective: The objective of this study was to review the contemporary clinical-stage pipeline of ASMs with novel or differentiated mechanisms of action, organized by molecular target, while placing recent regulatory successes and instructive failures within the broader transition toward mechanism-based, precision, and potentially disease-modifying therapies. Findings: A 2024 pipeline analysis identified more than 200 epilepsy therapies in preclinical or clinical development; at the cutoff of the present literature search (30 June 2026), over 40 compounds had reached phase II or III, with the majority directed at DEEs. Functional-state-selective sodium channel modulation has emerged as a leading conceptual advance supported by converging mechanistic and early clinical evidence, exemplified by relutrigine (PRAX-562), a preferential persistent-current inhibitor for which a regulatory decision is pending in SCN2A/SCN8A-DEEs, and vormatrigine (PRAX-628), whose large open-label effect was not reproduced in a controlled (blinded) trial. Several of the efficacy figures summarized here derive from congress presentations, interim analyses, or open-label extensions and await full peer-reviewed publication. Parallel advances include the selective Kv7 opener azetukalner; the dual-mechanism benchmark cenobamate; cholesterol-24-hydroxylase inhibition (soticlestat); selective serotonergic agonism (bexicaserin); glutamatergic precision agents (radiprodil); subtype-selective GABAA modulators (darigabat, ganaxolone); and gene-directed therapies (zorevunersen, elsunersen). Pre-symptomatic intervention in tuberous sclerosis complex provides an early, single-trial clinical proof of principle for delaying and reducing the incidence of epilepsy in a genetically defined population; this should not yet be equated with established disease prevention. Conclusions: The pipeline reflects an ongoing shift from broad symptomatic agents toward mechanism-led, genotype-matched, and potentially disease-modifying treatments. This shift is tempered by a persistent translational gap between early signals and randomized-trial confirmation, and by the preliminary status of much of the supporting evidence.

Open article ↗



2026-07-24 | Case Report: Induction of labor and postpartum management for fetal cardiac rhabdomyoma: a genetic etiology-based analysis of three cases.

Fetal cardiac rhabdomyoma (CR) is a rare primary cardiac tumor often linked to tuberous sclerosis complex (TSC) caused by TSC1/TSC2 mutations, yet its genetic heterogeneity and individualized perinatal management remain incompletely defined. This case series reports three primigravid women with fetuses diagnosed with CR at different gestational ages, who received induced labor via various regimens. Genetic testing identified a paternally inherited TSC2 mutation in one case, a de novo TSC1 mutation in another, while genetic analysis was declined in the third. Distinct differences exist in recurrence risk, long-term neurological prognosis and corresponding clinical decision-making between de novo TSC1 variants and paternally inherited TSC2 mutations, which fully reflects prominent genetic heterogeneity among TSC-related fetal CR. This study demonstrates the clinical and genetic heterogeneity of fetal CR, and highlights that ultrasound evaluation, TSC1/TSC2 genetic testing, and multidisciplinary care are crucial for guiding induction timing, perinatal management, and genetic counseling to improve perinatal outcomes.

Open article ↗



2026-03-09 | Neurogenetic tumor syndromes: The current landscape of workup and treatment.

Experts and generalists from numerous clinical disciplines are likely to encounter and be involved in the care of patients with neurogenetic tumor syndromes. Considerations for genetic testing are discussed. Specific conditions including neurofibromatosis type 1, neurofibromatosis type 2-related schwannomatosis, von Hippel-Lindau disease, tuberous sclerosis, Lynch syndrome, Turcot syndrome, Li-Fraumeni syndrome, and others are reviewed. A variety of targeted therapies which have received regulatory approval for these disorders are described and promising future directions for therapeutics are highlighted.

Open article ↗



2025-12-08 | Cerebellar tubers in tuberous sclerosis complex: MRI characteristics and longitudinal evolution in a pediatric and young adult cohort

Abstract Background Tuberous sclerosis complex (TSC) is a multisystem genetic disorder characterized by the development of benign tumors across multiple organ systems. While supratentorial cerebral manifestations are well documented, infratentorial involvement, particularly cerebellar tubers, remains less explored. This study aimed to evaluate the prevalence, imaging characteristics, and longitudinal changes of cerebellar tubers in patients with TSC. Methods A retrospective analysis was conducted on 61 pediatric and young adult patients diagnosed with TSC who underwent brain MRI between 2005 and 2023. MR imaging included standard sequences such as T1WI, T2WI, FLAIR, DWI, ADC mapping, SWI, and post-contrast T1WI. All scans were independently reviewed by three experienced neuroradiologists (each one with 15 years of experience); they were blinded to clinical data. Results Cerebellar tubers were identified in 29 out of 61 patients (47.5%), totaling 50 lesions. The most common morphology was wedge-shaped (96%). Signal intensity varied across sequences: T1 hypointense (92%), T2 hyperintense (86%), and FLAIR mixed patterns (variable). Enhancement after contrast administration was observed in 6% of tubers (striated pattern), and calcifications were present in 14%. Retraction deformities adjacent to tubers were noted in 48% of cases. Patients with cerebellar tubers had significantly more cerebral tubers than those without (mean: 29 vs 22; p < 0.001). Follow-up MRI in 13 patients (mean follow-up: 5.3 years) showed stability in 84.6%, slight regression in 7.7%, and progression in 7.7%. Conclusions Cerebellar tubers are relatively common in TSC and exhibit distinct morphological and signal characteristics. These lesions demonstrate dynamic behavior over time, correlating with supratentorial abnormalities and potentially influencing neurobehavioral outcomes. Awareness of these features can aid in early diagnosis and long-term monitoring.

Open article ↗



2025-12-03 | Renal epithelioid angiomyolipoma: A multi-institutional, international cohort study with emphasis on clinicopathologic prognostic indicators.

Renal angiomyolipoma (AML) is a benign perivascular epithelioid cell neoplasm that is often associated with tuberous sclerosis complex (TSC). Epithelioid AML (eAML), a very rare and potentially malignant variant, can be challenging to radiologically differentiate from benign AML and other renal tumors. Adverse histological features have previously been associated to poorer oncological outcomes. This study aimed to characterize this rare disease entity and validate previously reported adverse prognostic factors. This multicenter, retrospective cohort study analyzed 76 patients diagnosed with eAML between 2001 and 2024 across 15 participating centers. Inclusion criteria were histological diagnosis of eAML with negative cytokeratin markers and positive melanocytic markers. Patients were stratified according to previously described adverse pathological features. A total of 76 patients were studied. Most were female (70%), with a median age of 48 years and, 19 patients had TSC. Median tumor size was 45 mm, with a rate of atypical epithelioid cells >70% in 26 (34.2%) patients. According to the Nese's and Brimo's classifications, 4% and 14% of patients were at high risk, respectively. During a median follow- up of 30-months, 5 (6.7 %) patients developed metastases, and 4 (5.3 %) died. At univariable analysis, the number of adverse pathological risk factors, according to both classifications, was significantly associated with worse metastasis free survival (MFS) and cancer specific survival (CSS). Due to the low number of events, a multivariable analysis was not carried out. eAML is extremely rare, and primarily affects middle-aged women. This cohort validated previously described pathological risk factors for worse prognosis, suggesting that patients with multiple adverse features may require more intensive follow-up.

Open article ↗



oligonucleotides
2024-10-16 | Subependymal Giant Cell Astrocytoma: The Molecular Landscape and Treatment Advances.

Subependymal giant cell astrocytoma (SEGA) is most often found in patients with TSC (Tuberous Sclerosis Complex). Although it has been classified as a benign tumor, it may create a serious medical problem leading to grave consequences, including young patient demise. Surgery and chemotherapy belong to the gold standard of treatment. A broader pharmacological approach involves the ever-growing number of rapalogs and ATP-competitive inhibitors, as well as compounds targeting other kinases, such as dual PI3K/mTOR inhibitors and CK2 kinase inhibitors. Novel approaches may utilize noncoding RNA-based therapeutics and are extensively investigated to this end. The purpose of our review was to characterize SEGA and discuss the latest trends in the diagnosis and therapy of this disease.

Open article ↗



2024-08-23 | miR-25-5p in exosomes derived from UVB-induced fibroblasts regulates melanogenesis via TSC2-dominated cellular organelle dysfunction.

Few reports have confirmed whether exosomes derived from fibroblasts can regulate the process of melanogenesis. We wondered whether exosomes derived from fibroblasts could have a potent regulatory effect on melanogenesis and explored the underlying mechanisms. This study aimed to find the role of fibroblasts in melanocytes and revealed the related mechanisms. RT-qPCR, Western blot analysis were conducted to measure the RNA and protein expression level of various related genes. miRNA sequencing, mass spectrum analysis and subsequent bioinformatics analysis were employed to find the underlying targets. Zebrafish were employed to measure the melanin synthesis related process in vivo. Furthermore, electron microscopy, ROS measurement and dual-luciferase reporter assay were adopted to investigate the relationship between these processes. We found that exosomes derived from human primary dermal fibroblasts were internalized by human primary melanocytes and MNT1 cells and that the melanin content and the expression of melanin synthesis-related proteins TYR and MITF was inhibited by exosomes derived from UVB-induced human primary dermal fibroblasts. The miRNA expression profile in secreted exosomes changed significantly, with miR-25-5p identified as capable of regulating TSC2 expression via the CDS region. The miR-25-5p-TSC2 axis could affect the melanin content through subsequent cellular organelle dysfunction, such as mitochondrial dysfunction, endoplasmic reticulum stress and dysregulation of lysosomal cysteine proteases. We unveiled a novel regulatory role of fibroblasts in melanocytes, facilitated by the secretion of exosomes. miR-25-5p within exosomes plays a pivotal role in regulating melanogenesis via TSC2-induced cellular organelle dysfunction.

Open article ↗



2023-04-03 | MicroRNA Expression Profile in TSC Cell Lines and the Impact of mTOR Inhibitor.

The aim of this study was to assess the potential implication of microRNA on tuberous sclerosis (TSC) pathogenesis by performing microRNA profiling on cell lines silencing TSC1 or TSC2 genes using qPCR panels, before and after incubation with rapamycin. Significant differences in expression were observed between samples before and after rapamycin treatment in nineteen miRNAs in TSC1, five miRNAs in TSC2 and seven miRNAs in controls. Of miRNAs dysregulated before rapamycin treatment, three normalized after treatment in the TSC1 group (miR-21-3p, miR-433-3p, let-7g-3p) and one normalized in the TSC2 group (miR-1224-3p). Of the miRNAs dysregulated before rapamycin treatment in the TSC1 and TSC2 groups, two did not normalize after treatment (miR-33a-3p, miR-29a-3p). The results of the possible targets indicated that there are four common genes with seed regions susceptible to regulation by those miRNAs: ZBTB20, PHACTR2, PLXNC1 and ATP1B4. Our data show no changes in mRNA expression of these targets after rapamycin treatment. In conclusion, results of our study indicate the involvement of miRNA dysregulation in the pathogenesis of TSC. Some of the miRNA might be used as markers of treatment efficacy and autonomic miRNA as a target for future therapy.

Open article ↗



2022-10-27 | Extracellular vesicles derived from endometrial epithelial cells deliver exogenous miR-92b-3p to affect the function of embryonic trophoblast cells via targeting TSC1 and DKK3.

Extracellular vesicles (EVs) could mediate embryo-maternal communication to affect embryo implantation by delivering biology information, including microRNA (miRNA), protein, lipid. Our previous research shows that miR-92b-3p was differentially expressed in EVs of uterine flushing fluids during the embryo implantation period. However, the role of miR-92b-3p from EVs in embryo implantation remains elusive. EVs were isolated from porcine endometrial epithelial cells (EECs) by ultracentrifugation. MiR-92b-3p mimics and EVs were used to regulate the expression of miR-92b-3p in porcine trophoblast cells (PTr2 cells). Cell proliferation, migration and adhesion analyses were used to observe the phenotype. RT-qPCR, western blot and dual-luciferase reporter assay were used to assess the targets of miR-92b-3p. In this study, EVs derived from porcine EECs were identified and could be taken up by PTr2 cells. We found that the EVs derived from EECs transfected with miR-92b-3p mimic (EVs-miR-92b-3p) significantly promoted the proliferation, migration and adhesion of PTr2 cells. We verified that Tuberous sclerosis complex subunit (TSC1) and Dickkopf 3 (DKK3) were the target genes of miR-92b-3p. Moreover, our study showed that miR-92b-3p plays a vital role in PTr2 cells via targeting TSC1 and DKK3. Furthermore, the 3'UTR vectors of TSC1 and DKK3 can rescue the effect of miR-92b-3p on PTr2 cells. Taken together, this study reveals a novel mechanism that EVs derived from porcine EECs treated with miR-92b-3p crosstalk with trophoblasts by targeting TSC1 and DKK3, leading to an enhanced ability for implantation.

Open article ↗



2022-04-12 | Peripheral Serum Exosomes Isolated from Patients with Acute Myocardial Infarction Promote Endothelial Cell Angiogenesis via the miR-126-3p/TSC1/mTORC1/HIF-1α Pathway.

Angiogenesis is required for improving myocardial function and is a key factor in long-term prognosis after an acute myocardial infarction (AMI). Although exosomes are known to play a crucial role in angiogenesis, the role of peripheral exosomes in angiogenic signal transduction in patients with AMI remains unclear. Here, we explored the effect of exosomes extracted from the peripheral serum of AMI patients on angiogenesis and elucidated the downstream pathways. Serum exosomes were obtained from patients with AMI (AMI-Exo) and healthy individuals (Con-Exo). The exosomes were cocultured with human umbilical vein endothelial cells (HUVECs) in vitro, with aortic rings ex vivo, and were used to treat mouse hind-limb ischemia and mouse AMI model in vivo. AMI-Exo raised HUVEC proliferation, tube formation, and migration, and enhanced microvessel sprouting from aortic rings compared to Con-Exo, both in vitro and ex vivo. Quantitative reverse transcription-polymerase chain reaction revealed that the abundance of miR-126-3p, a crucial regulator of angiogenesis, was increased in AMI-Exo. The inhibition of miR-126-3p decreased the benefits of AMI-Exo treatment, and miR-126-3p upregulation enhanced the benefits of Con-Exo treatment in HUVECs, aortic rings, the mouse hind-limb ischemia model, and the mouse AMI model. Knockdown and overexpression analyses revealed that miR-126-3p regulated angiogenesis in HUVECs by directly targeting tuberous sclerosis complex 1 (TSC1). Moreover, we found that miR-126-3p could inhibit TSC1 expression, which further activated mTORC1 signaling and increased HIF-1α and VEGFA expression, ultimately promoting angiogenesis. Collectively, our results provide a novel understanding of the function of exosomes in angiogenesis post AMI. We demonstrated that exosomes from the peripheral serum of AMI patients promote angiogenesis via the miR-126-3p/TSC1/mTORC1/HIF-1α signaling pathway.

Open article ↗



other
2026-09-24 | mTORC1 drives cell-autonomous astrocyte reactivity in tuberous sclerosis.

Tuberous sclerosis complex (TSC) is a genetic neurodevelopmental disorder characterized by focal brain malformations called cortical tubers, which are associated with severe, intractable epilepsy1. Tubers are thought to result from somatic second-hit mutations that disrupt the TSC1 or TSC2 genes in neural progenitor cells, driving hyperactive mTORC1 signalling2. Glial abnormalities are commonly observed in tubers3; however, whether glia actively cause disease or merely result from chronic seizure activity has remained unclear. To address this question, we used human brain organoid models to track the developmental fate of mutated progenitor cells in the absence of seizures. Here we show, using single-cell transcriptomics and cyclic immunostaining across human brain organoids and resected tuber tissue from patients, that loss of TSC2 biases neural progenitors to differentiate into enlarged, pro-inflammatory reactive astrocytes in a cell autonomous manner. These mutant astrocytes show downregulated glutamate transporter expression, increased inflammatory cytokine secretion and elevated expression of neurodegenerative disease risk genes such as APOE and CLU. Our findings demonstrate that reactive astrocytes emerge as a primary consequence of TSC2 loss. These results implicate glial dysfunction as a driver of TSC pathogenesis and highlight reactive astrocytes as potential therapeutic targets for TSC-related neuropathology.

Open article ↗



2026-09-19 | Unilateral Fibrovascular Vitreoretinal Proliferation Associated With Retinal Astrocytic Hamartoma Revealing Tuberous Sclerosis Complex in Adulthood.

To report an unusual presentation of previously undiagnosed tuberous sclerosis complex manifesting as unilateral fibrovascular vitreoretinal proliferation associated with retinal astrocytic hamartoma complicated by vitreous hemorrhage (VH). A single case was reviewed. A 29-year-old woman presented with visual loss in the left eye and longstanding reduced vision since childhood. Examination revealed a retinal astrocytic hamartoma in the right eye and VH, fibrovascular vitreoretinal proliferation, retinal disorganization, and macular thickening in the left eye. Fluorescein angiography demonstrated telangiectatic vessels and late-phase leakage. The presence of accompanying cutaneous lesions prompted multidisciplinary evaluation, which revealed systemic tuberous sclerosis complex associated with a heterozygous TSC1 mutation. Following a single intravitreal injection of bevacizumab, regression of the VH and stabilization of the proliferative retinal findings were observed during 1 year of follow-up. Retinal astrocytic hamartomas associated with tuberous sclerosis complex are generally benign and asymptomatic; however, rare progressive forms may present with fibrovascular vitreoretinal proliferative complications. Ocular manifestations may play a critical role in diagnosing previously unrecognized tuberous sclerosis complex.

Open article ↗



2026-07-21 | mTORC1 activation induces B7-H3-dependent metabolic reprogramming in renal cell carcinoma (RCC).

Renal cell carcinoma (RCC) affects over 435,000 people worldwide each year and remains a significant cause of cancer mortality. Aberrant activation of pathways such as mTORC1 is frequently observed in RCC, yet the mechanisms by which mTORC1 contributes to tumor development remain poorly understood. The lack of suitable animal models has limited progress in uncovering these mechanisms and advancing targeted treatments. Here, we performed single-cell transcriptomic, proteomic, and metabolomic profiling of kidneys from mice with embryonic Tsc2 deletion at E17.5, which revealed a distinct tumor cell population characterized by intercalated cell signatures, co-expression of Foxi1 and Rhcg, and hyperactivated mTORC1. These lesions closely resemble human chromophobe renal cell carcinoma (ChRCC), a subtype of RCC. The tumors show marked upregulation of the immune checkpoint molecule B7-H3. Mechanistically, the transcription factor NRF1 is elevated in Tsc2-deficient lesions and drives B7-H3 expression in tumor cells. In human specimens, B7-H3 is broadly expressed in both classical and sarcomatoid ChRCC and correlates with hallmark markers FOXI1, MUC2, and HEPACAM2. Strikingly, B7-H3 deletion in mice suppresses Tsc2 loss-driven cystic and tumor formation, restores amino acid metabolism, and attenuates aminoacyl-tRNA biosynthesis and proteasome activity. Collectively, these findings identify B7-H3 as a functional driver of Tsc2-mediated ChRCC and a promising therapeutic target in TSC-associated renal tumors.

Open article ↗



2026-07-17 | GPR143, a novel immunohistochemical marker for renal tumors with FLCN/TSC/MTOR-TFE alterations.

Although several ancillary tests are available in limited laboratories, diagnosis of microphthalmia (MiT)/TFE family translocation renal cell carcinoma (tRCC) could be challenging due to diverse and overlapping tumor morphology and the lack of reliable biomarkers. GPNMB has been recently identified as a diagnostic marker for various renal neoplasms with FLCN/TSC/mTOR-TFE alterations. However, the sensitivity and specificity of GPNMB immunostain are suboptimal and the result interpretation in ambiguous cases could be difficult. To search additional biomarkers that could improve the screening sensitivity and predict genetic aberrations in FLCN/TSC/mTOR-TFE pathway in renal tumors, we performed bioinformatic analysis of publicly available cancer databases and found GPR143, a transmembrane protein regulated by MiT transcription factors, was highly expressed in a subset of renal cell carcinomas (RCCs). In two kidney cancer cohorts of the Cancer Genome Atlas (TCGA), RCCs with high levels of GPR143 expression were enriched for renal neoplasms with FLCN/TSC/mTOR-TFE alterations. Similar to GPNMB labeling, GPR143 immunostain was positive in the majority of tRCC cases and renal tumors with FLCN/TSC/mTOR alterations, suggesting that GPR143 could function as another surrogate marker for FLCN/TSC/mTOR-TFE alterations in certain renal tumors. Interestingly, despite the concordant GPR143 and GPNMB immunoreactivity in most renal neoplasms with FLCN/TSC/mTOR-TFE alterations, diffuse GPR143 immunostain was observed in some cases with negative or focal GPNMB labeling. Taken together, our results indicate GPR143 could serve as a useful adjunct marker to improve the sensitivity for screening renal tumors with FLCN/TSC/mTOR-TFE alterations.

Open article ↗



2026-05-31 | Long-term outcomes of selective arterial embolization in giant renal angiomyolipoma: A retrospective single-center study.

To evaluate the long-term outcomes of selective trans-arterial embolization (SAE) in patients with giant (⩾10 cm in size) renal angiomyolipomas (AMLs) at our tertiary referral center. This retrospective, single-center study included 44 patients who underwent SAE for AMLs of ⩾10 cm size between July 2018 and June 2024. Collected data included demographics, tumor characteristics, clinical symptoms, type of intervention, tumor size before and after embolization, and renal function. Outcomes assessed were tumor size reduction, preservation of renal function, reintervention rates during follow-up and complications following SAE. The study included 46 tumors in 44 patients. Mean patient age was 40.4 years (range: 23-60), with 86.3% being females. Mean follow-up duration was 25.2 months (range: 6-70 months). Eleven patients (25%) were associated with TSC, and all were offered Everolimus postoperatively. The mean tumor size decreased significantly from 13.2 ± 3.12 cm pre-embolization to 10.3 ± 2.45 cm post-embolization (p = 0.003). Renal function remained stable during follow-up, with no significant changes in serum creatinine (p = 0.6) and eGFR (p = 0.8). The overall success rate was 84.7%, with 13.6% experiencing re-intervention. Complications included post-embolization syndrome (43.1%) and allergic reactions (6.8%), while one patient required nephrectomy due to a perinephric abscess. Selective Trans-arterial Embolization is a safe and effective treatment for giant renal AMLs, resulting in significant tumor size reduction, symptom relief, and preservation of renal function. It offers a minimally invasive alternative to traditional surgical approaches, particularly for patients with high surgical risk or those requiring nephron-sparing procedure.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

19 orphan drug designations for Tuberous sclerosis complex, including 5 approved therapies.

19 orphan drug designations for Tuberous sclerosis complex, including 5 approved therapies.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

a potent, CNS active selective inhibitor of mTORC1

small molecules

FDA
2026-02-03

—

LBR Regulatory and Clinical Consulting Services, Inc.

vigabatrin

small molecules

FDA
2024-11-02

Phase II/III
Ongoing

Pyros Pharmaceuticals Inc

Ganaxolone

small molecules

EMA
2021-10-15

Phase III
Terminated

Immedica Pharma AB

ganaxolone

small molecules

FDA
2021-08-12

Phase III
Terminated

Immedica Pharma AB

sirolimus

small molecules

FDA
2019-08-26

Phase III
Ongoing

AI Therapeutics, Inc.

Cannabidiol [Epidyolex]

small molecules

EMA
2018-01-17

Approved
2021-04-20

Jazz Pharmaceuticals Ireland Limited

Sirolimus [Hyftor]

small molecules

EMA
2017-08-23

Approved
2023-05-26

Plusultra Pharma GmbH

Sirolimus

small molecules

EMA
2017-06-20

Phase III
Ongoing

Desitin Arzneimittel GmbH

sirolimus [Hyftor]

small molecules

FDA
2017-05-17

Approved
2022-03-22

NobelPharma Co., LTD

sirolimus

small molecules

FDA
2017-02-13

Phase III
Ongoing

Aucta Pharmaceuticals, Inc.

cannabidiol [Epidiolex]

small molecules

FDA
2016-04-19

Approved
2020-07-31

Jazz Pharmaceuticals Research UK Limited

rapamycin

small molecules

FDA
2016-02-24

Phase III
Ongoing

AFT Pharmaceuticals Ltd.

Sirolimus

small molecules

EMA
2015-10-09

Phase III
Ongoing

Desitin Arzneimittel GmbH

everolimus ointment

small molecules

FDA
2015-09-10

Phase III
Ongoing

Aucta Pharmaceuticals, LLC

Everolimus [Votubia]

small molecules

EMA
2010-08-04

Phase III
Terminated

Novartis Europharm Limited

everolimus [Afinitor]

small molecules

FDA
2009-06-08

Approved
2010-10-29

Novartis Pharmaceuticals Corp.

rapamycin

small molecules

FDA
2007-03-20

Phase III
Ongoing

OncoImmune, Inc.

Polyethylene glycol-modified uricase

—

FDA
1999-09-14

Phase II
Terminated

Swedish Orphan Biovitrum AB

Polyethylene glycol-modified uricase

—

FDA
1998-12-21

—

Swedish Orphan Biovitrum AB

“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.